Rein Therapeutics Inc.
RNTX
$1.36
-$0.12-8.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.55% | 23.71% | 22.66% | -458.40% | -220.03% |
| Total Depreciation and Amortization | -- | -75.00% | -- | -100.00% | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 263.58% | -21.47% | 76.00% | 8,188.62% | 173.12% |
| Change in Net Operating Assets | -87.76% | -34.08% | -157.44% | 72.86% | 13,918.18% |
| Cash from Operations | 7.10% | 23.50% | -17.15% | 53.69% | -132.87% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -88.70% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -52.04% | -- | -- | -- |
| Cash from Financing | 526.01% | -74.20% | -- | -99.99% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | 98.41% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.75% | -117.28% | -3.15% | -191.76% | -288.43% |